In support, blockade of HSP27 overcomes BTZ resistance in lymphoma cells [29] while in a mouse myeloma model, resistance-related gene signatures were enriched for expression of nrf2 [30]. This evidence concerns the gene HSPB1 and plasma cell myeloma.